Pharma & Life Sciences — March 27, 2026

Nonregulated Status Determination for MON 95275 Maize

The Animal and Plant Health Inspection Service (APHIS) has determined that MON 95275 maize, developed using genetic engineering for insect resistance, is no longer a regulated article. This determination, effective March 19, 2026, follows a review of submitted data, risk assessments, and public comments.

MEILUX Trademark Published for Opposition

The USPTO has published the MEILUX trademark for opposition, covering a range of pharmaceutical and cosmetic products. The application was filed on November 19, 2025, and published for opposition on March 26, 2026.

MAGNFIX trademark published for opposition

The USPTO has published the MAGNFIX trademark for opposition. The application covers a range of products including biocides, fungicides, disinfectants, and agricultural preparations for seed treatment and crop protection. The filing date was October 2, 2025.

RXILIENT Trademark Application Published for Opposition

The USPTO has published the trademark application for 'RXILIENT' for pharmaceutical products, initiating a 30-day opposition period. The application, filed on November 19, 2025, covers a wide range of pharmaceutical preparations and dermatological products.

ATTOCONEXA Trademark Application Published for Opposition

The USPTO has published the trademark application for ATTOCONEXA, filed by a pharmaceutical entity. This publication initiates a period for opposition before the trademark can be officially registered.

VALALTO Trademark Application Published for Opposition

The USPTO has published the VALALTO trademark application for opposition. The application covers a wide range of goods and services, including pharmaceuticals, dietetic foods, and retail services related to these products. The publication initiates a period during which third parties may oppose the registration of the mark.

MBIOSEQ Trademark Application Published for Opposition

The USPTO has published the trademark application for MBIOSEQ for opposition. The application covers reagents, assays, software, and instruments related to medical diagnostics, molecular biology, and laboratory testing. The filing date was November 18, 2025.

FREEMOVERS trademark published for opposition

The USPTO has published the FREEMOVERS trademark application for opposition. The application, filed on November 18, 2025, covers babies' diapers and diaper-pants. The publication date for opposition is March 26, 2026.

POKéMON Trademark Application TM79436893 Published

The USPTO published trademark application TM79436893 for POKéMON, covering a wide range of goods including clothing, electronics, food supplements, pet supplies, and digital media. The publication marks the beginning of the opposition period for this application.

VITBLISS Trademark Application Published for Opposition

The USPTO has published the trademark application for VITBLISS, filed on October 2, 2025, for opposition. The application covers dietary supplements and dietetic preparations. The publication date is March 26, 2026.

CILIATECH trademark application published for opposition

The USPTO has published the trademark application for CILIATECH, which covers a range of goods and services related to ophthalmology, including medical research, prostheses, implants, and pharmaceutical products. The application was published for opposition on March 26, 2026.

WECHECK trademark application published for diagnostic reagents

The USPTO published the trademark application for 'WECHECK' on March 26, 2026. The application covers diagnostic reagents and test strips for medical purposes, including blood glucose monitoring. This publication opens a period for opposition before the trademark is granted.

Kizefma Trademark Published for Opposition

The USPTO has published the trademark application for 'Kizefma' for opposition. The application covers various medical and pharmaceutical uses, including treatments for arthritis, spondylitis, psoriasis, and autoimmune diseases. The filing date was October 16, 2025.

IXCLERMA Trademark Published for Opposition

The USPTO has published the trademark application for IXCLERMA for opposition. The application covers pharmaceutical preparations for the treatment of various medical conditions, including arthritis, spondylitis, psoriasis, and autoimmune diseases.

KKV Trademark Application Published for Opposition

The USPTO has published the KKV trademark application for opposition. The application covers a wide range of goods including medical supplies, food products, household appliances, tools, chemicals, paper goods, textiles, and more. The publication allows for a period where third parties can oppose the trademark registration.

SECRETECH Trademark Publication for Opposition

The USPTO has published the SECRETECH trademark application (TM79437413) for opposition. The application covers a range of goods and services including diagnostic reagents, sterilizing preparations, nutraceuticals, and scientific research services.

Trademark 79441140 Published for Opposition

The USPTO has published trademark application 79441140 for opposition. The application covers a wide range of food products, including flour, cereals, confectionery, noodles, and baby food, as well as dietary supplements and preparations for medical use. The filing date for this application was November 18, 2025.

FARCO trademark published for opposition

The USPTO has published the FARCO trademark application for opposition. The application covers pharmaceutical preparations for use in urology and sanitary preparations for medical purposes. The publication date was March 26, 2026.

KIZELMY Trademark Application Published for Opposition

The USPTO has published the KIZELMY trademark application for opposition. The application, filed on October 16, 2025, covers pharmaceutical preparations for treating various medical conditions. The publication opens a period for third parties to oppose the trademark registration.

Valalto Life Beyond Care Trademark Application Published

The USPTO has published the trademark application for 'Valalto Life Beyond Care' for opposition. The application covers a wide range of goods and services, including pharmaceuticals, dietetic foods, and retail services for medical supplies. The publication date is March 26, 2026.

New Trademark Application Published for Opposition

The USPTO has published a new trademark application for opposition, related to veterinary preparations and animal dietary supplements. The application was filed on November 18, 2025, and the opposition period begins March 26, 2026.

ATTOSCRIPTA Trademark Application Published for Opposition

The USPTO has published the trademark application for 'ATTOSCRIPTA' for opposition. The application covers a wide range of research reagents, diagnostic preparations, and chemicals for scientific and industrial use, primarily within the pharmaceutical and biotechnology sectors. The publication opens a period for third parties to oppose the trademark registration.

NEUTOUQ Trademark Application Published for Opposition

The USPTO has published the trademark application for 'NEUTOUQ' for opposition. The application covers a wide range of goods and services, including non-medicated cleansers, cosmetics, textiles, and wholesale/retail store services for pharmaceutical and medical supplies.

SIGMIR Trademark Application Published for Opposition

The USPTO has published the SIGMIR trademark application for opposition, related to microbial inoculants, seed treatments, and agricultural chemicals. The application was published on March 26, 2026, following a filing date of September 17, 2025.

Hepatofilin Trademark Application Published for Opposition

The USPTO has published the trademark application for 'Hepatofilin' for opposition. The application covers nutritional supplements, herbal teas for medicinal purposes, and medicinal drinks. The publication date is March 26, 2026.

ATTOAPOLLO Trademark Application Published for Opposition

The USPTO has published the ATTOAPOLLO trademark application for opposition. This trademark application covers a wide range of research preparations, reagents, and diagnostic tools for medical, veterinary, and scientific research purposes. The publication marks a step in the trademark registration process, allowing for potential objections before final approval.

ATTOIRIDA Trademark Application Published for Opposition

The USPTO has published the ATTOIRIDA trademark application for opposition. The application covers a broad range of chemicals, reagents, and research preparations for industrial, scientific, and diagnostic use, including those related to pharmaceuticals and biotechnology. The publication opens a period for third parties to oppose the trademark registration.

SAQUELTA Trademark Application Published for Opposition

The USPTO has published the trademark application for SAQUELTA, related to pharmaceutical and medical preparations for treating cancers and dermatological diseases. The application was published for opposition on March 26, 2026, with a filing date of November 19, 2025.

YUMIVET Trademark Publication for Opposition

The USPTO has published the YUMIVET trademark application for opposition. The application, filed on November 19, 2025, covers veterinary products and chemical preparations for medical use. The publication date for opposition is March 26, 2026.

Bruker Mbioseq Trademark Application Published for Opposition

The USPTO has published the trademark application for 'Bruker Mbioseq' for opposition. The application covers reagents, assays, and software related to medical diagnostics, molecular biology, and laboratory apparatus. The filing date was November 18, 2025.

TIRAMAZ Trademark Application Published

The USPTO has published the trademark application for TIRAMAZ, filed on September 29, 2025. The application covers chemicals for industrial, agricultural, horticultural, and forestry use, including fertilizers, biostimulants, and plant growth regulators. This publication marks a step in the trademark registration process.

CMS Seeks Public Comment on Information Collection Activities

The Centers for Medicare & Medicaid Services (CMS) is seeking public comment on its intention to collect information from the public, as required by the Paperwork Reduction Act. This notice provides an opportunity for comment on the necessity, utility, and burden estimates of proposed information collections, including a revision for the Social Security Office (SSO) Report of State Buy-in Problems.

Comment on CMS Agency Information Collection Activities notice

The Centers for Medicare and Medicaid Services (CMS) is providing a notice regarding agency information collection activities. This notice allows the public to submit comments on the activities, which may include data collection forms or surveys used by CMS.

Proposed TANF Pilot Evaluation Information Collection Activity

The Department of Health and Human Services (HHS) is proposing to collect data for a new Temporary Assistance for Needy Families (TANF) Pilot Evaluation. This initiative, authorized by the Fiscal Responsibility Act of 2023, aims to test new outcomes-based performance benchmarks in the TANF program. Public comments are being solicited on the proposed data collection instruments.

Proposed 30-Day Comment Request: Clinical Trials Reporting Program Database

The National Institutes of Health (NIH) is seeking public comment on a proposed extension for the Clinical Trials Reporting Program (CTRP) Database. This notice provides an additional 30-day comment period for the data collection project, which aims to consolidate reporting for NCI-supported clinical research.

CMS Proposes Information Collection; Seeks Public Comment

The Centers for Medicare & Medicaid Services (CMS) has published a notice proposing to collect information and is seeking public comment. The comment period for this proposed collection ends on May 26, 2026.

Bayer CropScience: Determination of Nonregulated Status of MON 95275 Maize

The Animal and Plant Health Inspection Service (APHIS) has determined that MON 95275 maize, genetically engineered for insecticidal properties, is no longer a regulated article. This determination follows a review of submitted data and public comments, recognizing the change in regulatory status as of March 19, 2026.

ECHA Publications on PFAS Restriction Proposal and Consultation

ECHA has published updates regarding a proposed restriction on PFAS substances. These include a draft opinion from the Socio-Economic Analysis Committee, an upcoming public consultation on this opinion, and ECHA's support for the restriction with targeted derogations. The consultation period will run from March 26 to May 25, 2026.

Blueroot Health Recalls Aller-C Supplements for Undeclared Allergens

Blueroot Health is voluntarily recalling two lots of Vital Nutrients Aller-C dietary supplements due to undeclared egg, hazelnut, and soy. The recall affects nationwide distribution, and consumers with allergies to these ingredients are advised to return the product. No illnesses have been reported to date.

NIH Center for Scientific Review Announces Closed Meetings

The National Institutes of Health (NIH) has published a notice announcing several upcoming closed meetings for the Center for Scientific Review. These meetings, scheduled for April 2026, will involve the review and evaluation of grant applications, which may contain confidential commercial or personal information.

Advisory Committee on Immunization Practices Meeting Cancellation

The Centers for Disease Control and Prevention (CDC) has issued a notice cancelling the Advisory Committee on Immunization Practices (ACIP) meeting previously scheduled for March 18-19, 2026. This cancellation is due to a court order in the case American Academy of Pediatrics et al. v. Kennedy et al.

Lead Exposure and Prevention Advisory Committee Charter Renewal

The Centers for Disease Control and Prevention (CDC) has renewed the charter for the Lead Exposure and Prevention Advisory Committee (LEPAC). The renewal is effective for a two-year period, extending through March 11, 2028.

Electric Scalpel HF Bipolar Cable Safety Information

The ANSM has issued a safety alert regarding an action taken by Olympus Winter & IBE GmbH concerning their electric scalpel HF bipolar cable. Healthcare facilities have been informed of this safety action, registered under number R2607994.

EMA CHMP Meeting: 5 New Medicines, 13 Indication Extensions Recommended

The EMA's CHMP recommended five new medicines for approval and extensions of therapeutic indications for 13 existing medicines at its March 2026 meeting. The committee also confirmed a refusal for a marketing authorisation change and noted the withdrawal of an application for a new Alzheimer's treatment.

Ketorolac Tromethamine Ophthalmic Solution Revision Notice

The USP has issued a notice of intent to revise the Ketorolac Tromethamine Ophthalmic Solution monograph. The revision aims to extend the official date and adjust the pH limit from 6.8-7.9 to 6.2-7.9 to accommodate FDA-approved products.

General Chapter Prospectus for LG Polymer Implant Drug Products

The USP has issued a General Chapter Prospectus for <1158> LG Polymer Implant Drug Products – Characterization Methods. This proposed chapter aims to provide a compendial framework for product quality and performance testing of LG polymer implant drug products, focusing on specific characterization needs for these long-acting dosage forms. Stakeholders are invited to provide input.

Levocarnitine Monograph Revision: Proposed Direct Chiral HPLC Method

The USP has proposed a direct chiral HPLC method to revise the Enantiomeric Purity test in the Levocarnitine monograph due to the temporary unavailability of the required derivatization reagent (+)-FLEC. This proposed method is currently open for public comment.

USP Revises Select Chemical Standards

The USP has announced revisions to the chemical information of select standards, with updates becoming official on October 1, 2026. These changes affect specific USP monographs for various drug substances and formulations, including Candesartan Cilexetil and Hydrochlorothiazide Tablets, Dronabinol, and several Verapamil Hydrochloride products.

USP-NF Changes: Redesign-Only Standards Official Date Policy

The United States Pharmacopeia (USP) has updated its policy regarding the official date for "redesign-only" documentary standards in the USP-NF Online platform. Previously, these standards retained their original publication date, but now they will have a "To Be Official" status and become official six months after posting, effective March 27, 2026.

Michigan Medicaid: Diabetes/Weight Loss Drugs Dispensed Per Requirements

The HHS Office of Inspector General (OIG) reported that selected diabetes and weight loss drugs dispensed to Michigan Medicaid managed care enrollees were in accordance with federal and state requirements. The audit found that Michigan ensured managed care organizations followed all applicable coverage and utilization requirements, including prior authorizations and quantity limits.

TUV SUD America Application for Yonezawa

The Occupational Safety and Health Administration (OSHA) has published an application from TUV SUD America regarding Yonezawa. This notice serves as an informational update on the application's status within the agency's regulatory process.

Guidance on Incorporating Voluntary Patient Preference Information

The FDA has issued updated guidance on incorporating voluntary patient preference information (PPI) into medical device submissions. This guidance provides recommendations on methods and contexts for collecting and submitting PPI to aid FDA decision-making throughout the total product lifecycle for biologics and medical devices.

Adipopharma Trademark Application Published for Opposition

The USPTO has published the Adipopharma trademark application (TM79425256) for opposition. The application covers scientific and technological services related to drugs and pharmaceuticals, as well as various pharmaceutical and veterinary preparations.

Pharmalys Laboratories Trademark Application Published for Opposition

The USPTO has published the trademark application for 'P Pharmalys Laboratories' for opposition. The application covers a range of pharmaceutical products, dietary supplements, and medical foods. The publication date is March 26, 2026, with a filing date of September 19, 2025.

Mabquest Therapeutics Trademark Application Published for Opposition

The USPTO has published the trademark application for 'Mabquest Therapeutics' for opposition. The application covers pharmaceutical products for treating cancer, autoimmune diseases, and inflammatory disorders, among other related medical preparations and diagnostic agents. The publication date is March 26, 2026, with a filing date of July 29, 2025.

DEA Houston Fentanyl Message at Baseball Game

The DEA's Houston Division participated in a public outreach event at a baseball game on March 26, 2026, to spread awareness about fentanyl. The division set up a booth to distribute educational materials and giveaways.

MHRA Guidance on Clinical Trials Quality and Risk Proportionality

The MHRA has issued new draft guidance on applying quality by design, risk-based quality management, and proportionate oversight in UK clinical trials. This guidance accompanies amendments to the Medicines for Human Use (Clinical Trials) Regulations 2004, which come into force on April 28, 2026. The agency is seeking feedback on the draft guidance.

Medline Namic Angiographic Control Syringes Recalled Due to Unwinding Risk

Health Canada has issued a Type I recall for Medline Namic Angiographic Control Syringes due to a risk of the syringe rotating adaptor unwinding during use, which could lead to procedural delays or death. Healthcare professionals are advised to contact the manufacturer for more information and to destroy affected products.

SFDA CEO Congratulates Saudi Leadership on Eid al-Fitr

The CEO of the Saudi Food and Drug Authority (SFDA) extended Eid al-Fitr greetings to the Saudi leadership and people. The announcement also highlighted the SFDA's role in ensuring the safety of food, medicine, and medical devices during the Umrah season.

SFDA grants orphan drug designation to Sephience for HPA/PKU

SFDA grants orphan drug designation to Sephience for HPA/PKU

SFDA Grants Breakthrough Designation to Bemlayo for Obesity/Overweight

The Saudi Food and Drug Authority (SFDA) has granted Eli Lilly's drug Bemlayo (Orforglipron) Breakthrough designation. This designation expedites the review process for innovative treatments for serious diseases but does not constitute marketing authorization.

SFDA Grants Orphan Drug Designation to Agamree for Duchenne Muscular Dystrophy

The Saudi Food and Drug Authority (SFDA) has granted Santhera Pharmaceuticals orphan drug designation for Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD). This designation allows for a dedicated regulatory pathway for serious or rare diseases but does not constitute formal product registration.

SFDA CEO Discusses AI's Role in Drug Development and Regulatory Efficiency

The CEO of the Saudi SFDA highlighted the significant contributions of Artificial Intelligence (AI) to accelerating drug development, reducing costs, and enhancing regulatory efficiency for medicines, medical devices, and food products. The SFDA has launched an AI laboratory and developed a digital twin to integrate emerging innovations and streamline approval processes.

Pharmacy Policy on Reporting Loss or Theft of Controlled Substances

The Massachusetts Board of Registration in Pharmacy has issued Policy 2026-01, updating procedures for pharmacies and wholesalers to report confirmed losses or thefts of controlled substances. The policy requires reporting within 7 calendar days of discovery for all losses related to theft, pilferage, or diversion, regardless of quantity or schedule, and significant losses of Schedule II-VI substances.

Pharmacy Reporting Policy for Controlled Substance Loss or Theft

The Massachusetts Board of Registration in Pharmacy has issued Policy 2026-01, updating procedures for licensed pharmacies and wholesalers to report confirmed losses or thefts of controlled substances. The policy requires reporting within 7 days of confirmed losses, including those from theft, pilferage, or diversion, regardless of quantity or schedule, and significant losses of Schedule VI substances.

Sunshine Act Meeting Cancellation

The Federal Mine Safety and Health Review Commission has cancelled its Sunshine Act meeting previously scheduled for March 26, 2026. The cancellation notice was published on March 24, 2026, and supersedes a previous announcement from March 10, 2026.

ECO ORIGIN Trademark Publication

The USPTO has published the ECO ORIGIN trademark application for opposition. The application covers the supply and distribution of various medical gases. The publication date is March 26, 2026, with a filing date of May 5, 2025.

Composition for Regulating Interfering Ribonucleic Acid Production

The USPTO has published a new patent application (US20260085312A1) detailing compositions and methods for regulating interfering ribonucleic acid (miRNA) production. The application describes techniques to decrease the bioavailability of target biomolecules by degrading or inactivating their corresponding messenger RNA (mRNA).

USPTO Patent Application for Modulating SMN2 RNA and Protein

The USPTO has published a patent application (US20260085313A1) detailing compounds, methods, and pharmaceutical compositions for modulating SMN2 RNA and protein. This application, filed on May 2, 2025, aims to ameliorate symptoms of neurodegenerative disorders.

Conjugated Oligonucleotide Compounds for Therapeutic Use

The USPTO has published a new patent application (US20260085314A1) for conjugated oligonucleotide compounds, methods of making them, and their therapeutic uses. The application was filed on May 16, 2025, by inventors Ahmad Ali Mortazavi, Viviana Mannella, and Muthusamy Jayaraman.

HMBOX1 Inhibitor for Muscle Atrophy Treatment

The USPTO has published a patent application (US20260085316A1) from Shanghai University detailing the use of a homeobox containing 1 (HMBOX1) inhibitor for the prevention and treatment of muscle atrophy. The application outlines findings from cellular and animal studies supporting the therapeutic potential of inhibiting HMBOX1 expression.

siRNA for AGT gene expression inhibition in hypertension treatment

The USPTO has published a new patent application (US20260085317A1) detailing modified oligonucleotide sequences designed as siRNAs to inhibit angiotensinogen (AGT) gene expression. The application suggests these siRNAs may be used in the development of treatments for hypertension and related diseases.

Patent Application: Cancer Treatment with Stat3 Decoy

The USPTO has published a new patent application (US20260085318A1) detailing methods for treating cancer using a STAT3 double-stranded, cyclic oligonucleotide decoy in combination with an immune checkpoint inhibitor. The application was filed on September 20, 2023, by inventors Daniel E. Johnson and Jennifer R. Grandis.

Engineered Polynucleotide for Cancer Treatment

The USPTO has published a patent application detailing an engineered polynucleotide designed to treat cancer by regulating gene expression. The application, filed on July 17, 2025, describes compositions and methods involving polynucleotides that interact with pre-mRNA and spliceosomes.

Patent Application for cDNA Synthesis and Transcriptome Profiling

The USPTO has published a patent application (US20260085309A1) for compositions and methods related to cDNA synthesis and transcriptome profiling. The application details optimized template switching oligonucleotides designed to improve reverse transcription specificity and prevent concatemer formation. This is a new patent application filing, not a final rule or guidance.

Patent Application for Antisense Oligonucleotide Targeting TDP-43 mRNA

The USPTO has published a patent application (US20260085310A1) filed by NIPPON SHINYAKU CO., LTD. The application describes an antisense oligonucleotide targeting TDP-43 mRNA or pre-mRNA for potential therapeutic use. The filing date was May 26, 2023.

Patent Application: Compositions and Methods for Reducing RNA Levels

The USPTO has published a new patent application (US20260085311A1) detailing compositions and methods for reducing RNA levels and treating diseases caused by toxic gain-of-function proteins. The application was filed on June 20, 2023.

Patent Application for Dichrostachys glomerata Health Benefits

The USPTO has published a patent application (US20260083794A1) detailing methods and compositions using Dichrostachys glomerata for various health benefits, including reducing anxiety and improving mood. The application was filed on September 26, 2024, and is expected to be published on March 26, 2026.

Patent Application for Cancer Treatment Combination Therapies

The USPTO has published a new patent application (US20260083816A1) detailing methods for treating cancer using combination therapies. The application, filed by inventors Erlinda M. Gordon and Fredrick L. Hall, focuses on inhibiting cyclin proteins and targeting pathways that promote cyclin activity.

USPTO Patent Application for Dietary Supplement Formulation

The USPTO has published a patent application (US20260083814A1) for a dietary supplement formulation designed to alleviate sciatica pain and support nerve and musculoskeletal health. The application details a specific blend of natural ingredients and their purported benefits, filed on September 26, 2024.

Patent Application for Reducing DPP-4 Activity with Plants

The USPTO has published a new patent application (US20260083813A1) detailing methods and compositions using plants like Dichrostachys glomerata or Cissus quadrangularis to reduce DPP-4 activity or levels in mammals. The application was filed on September 26, 2024.

Patent Application: Reducing Fasting Blood Glucose Using Plants

The USPTO has published a new patent application detailing methods and compositions for reducing fasting blood glucose using plants like Dichrostachys glomerata or Cissus quadrangularis. The application, filed on September 26, 2024, describes oral dosage forms for health benefits including increased GLP-1 levels and reduced blood lipids.

Patent Application: Reducing Blood Lipids Using Plants

The USPTO has published a patent application (US20260083811A1) detailing methods and compositions for reducing blood lipids using plants like Dichrostachys glomerata or Cissus quadrangularis. The application, filed on September 26, 2024, describes compositions aimed at increasing GLP-1 levels and reducing visceral fat, food intake, blood lipids, total cholesterol, and total glucose.

Patent Application: Reducing Visceral Fat Using Plants and Spices

The USPTO has published a new patent application (US20260083810A1) detailing methods and compositions for reducing visceral fat in mammals using plants and spices such as Dichrostachys glomerata or Cissus quadrangularis. The application was filed on September 26, 2024, and is scheduled for publication on March 26, 2026.

Patent Application: Reducing Food Intake Using Plants

The USPTO has published a new patent application (US20260083809A1) detailing methods and compositions using plants like Dichrostachys glomerata or Cissus quadrangularis to reduce food intake or appetite in mammals. The application was filed on September 26, 2024, and is expected to be published on March 26, 2026.

Antiviral Fungal Extracts Prevent Coronavirus Infections

The USPTO has published a patent application (US20260083788A1) detailing antiviral fungal extracts that may prevent coronavirus infections by interfering with the Spike protein. The application, filed by Mycotech Pharma AS, describes compositions derived from Agaricus blazei, Grifola frondosa, and Hericium erinaceus.

US Patent Application for Heart Boosting Formulation

The USPTO has published a new patent application (US20260083806A1) for a heart boosting formulation. The application details a specific composition including L-carnitine, alpha-linolenic acid, citrulline, vitamin D3, lycopene, holy basil, cinnamon, and beetroot, along with related manufacturing methods. The filing date was September 16, 2025.

Patent Application for Dichrostachys glomerata to Reduce Anxiety and Improve Mood

The USPTO has published a patent application (US20260083797A1) detailing methods and compositions using Dichrostachys glomerata to reduce anxiety, food cravings, and stress, and to improve mood, energy, and overall health in mammals. The application was filed on September 26, 2024.

Patent Application for Dichrostachys glomerata to Reduce Anxiety and Stress

The USPTO has published a new patent application (US20260083796A1) detailing methods and compositions using Dichrostachys glomerata to reduce anxiety, stress, and food cravings, while improving mood and overall health in mammals. The application was filed on September 26, 2024, by inventor Shil Kothari.

Patent Application: Dichrostachys glomerata for Anxiety and Stress Reduction

The USPTO has published a patent application (US20260083793A1) detailing methods and compositions using Dichrostachys glomerata to reduce anxiety, stress, and food cravings, while improving mood and energy. The application was filed on September 25, 2024, by inventor Shil Kothari.

Patent Application for Dichrostachys glomerata to Reduce Anxiety and Cravings

The USPTO has published a new patent application (US20260083792A1) for methods and compositions using Dichrostachys glomerata to reduce anxiety, stress, food cravings, and improve mood and overall health. The application was filed on September 25, 2024, by inventor Shil Kothari.

Patent Application: Dichrostachys glomerata Health Benefits

The USPTO has published a patent application (US20260083791A1) detailing methods and compositions using Dichrostachys glomerata for various health benefits, including reducing anxiety, food cravings, and stress, and improving mood and energy. The application was filed on September 25, 2024, by inventor Shil Kothari.

Formulation for Hair Growth

The USPTO has published a new patent application, US20260083789A1, for a formulation designed to stimulate hair growth and improve hair quality. The formulation primarily utilizes a nitrate-enriched extract of Amaranth, along with other plant-based ingredients. The application details the method of preparation and its potential use in enhancing hair growth rate, count, and density.

GABA-producing bacteria for improving health patent application

The USPTO has published a new patent application (US20260083786A1) detailing a composition comprising Lactobacillus brevis (NCIMB 41903) for use in regulating or treating metabolic diseases. The application was filed on September 17, 2025, by inventors Paul Ross and Catherine Stanton.

Patent Application: Bifidobacterium longum for Infant Infection Prevention

The USPTO has published a patent application (US20260083785A1) detailing the use of Bifidobacterium longum transitional microorganisms to prevent or reduce the risk of infection in infants and young children. The application was filed on September 27, 2023.

FDA Acknowledgment Letter to Ingram Planetarium

The Food and Drug Administration (FDA) has issued an acknowledgment letter to Ingram Planetarium regarding a submission. The letter, dated March 26, 2026, confirms receipt of documentation from the Center for Devices and Radiological Health (CDRH). No specific details about the submission's content or regulatory implications are provided.

FDA CDRH Variance Approval Letter to Axion Laser

The FDA's Center for Devices and Radiological Health (CDRH) has issued a variance approval letter to Axion Laser. This document grants a specific variance, indicating an approved deviation from standard regulatory requirements for a particular product or process.

FDA Decision on Tradipitant New Drug Application Refusal

The Food and Drug Administration (FDA) has issued a final decision regarding the new drug application for Tradipitant. The agency has decided to refuse to approve the application, based on a proposal to do so. The specific details of the decision are confidential business information, but a redacted version is available.

FDA Final Response Letter to Athyna Pharma LLC

The Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has issued a final response letter to Athyna Pharma LLC. This document provides specific feedback and guidance related to the company's pharmaceutical development or regulatory submissions.

FDA Variance Request from Laina Callow - Comment Period Closed

The Food and Drug Administration (FDA) has closed the comment period for a variance request submitted by Laina Callow. The application, authored by CDRH, was available for public comment on regulations.gov.

FDA Acknowledges Letter to DePaul University

The Food and Drug Administration (FDA) has acknowledged receipt of a letter from DePaul University's Idea Realization Laboratory. This notice serves as an acknowledgment of the correspondence, with no further regulatory action or guidance provided at this time.

FDA Acknowledgement Letter to Premier Research International, LLC

The Food and Drug Administration (FDA) has issued an acknowledgement letter to Premier Research International, LLC. This notice confirms receipt of a submission, though no specific details about the submission's content or regulatory implications are provided.

FDA CDER Final Response Letter to Age Reversal Unity

The FDA's Center for Drug Evaluation and Research (CDER) has issued a final response letter to Age Reversal Unity regarding their submissions. The document is available through the Regs.gov portal.

FDA Acknowledgment Letter to Laina Callow

The Food and Drug Administration (FDA) has issued an acknowledgment letter to Laina Callow regarding a submission. The document is a redacted version of an acknowledgment letter from the FDA's Division of Management and Budget (DMB) to Laina Callow, authored by CDRH.

Citizen Petition Filed by Premier Research International LLC

Premier Research International LLC has filed a citizen petition with the Food and Drug Administration (FDA) regarding regulatory matters. The petition is available for public review and comment.

FDA Variance Application from Ingram Planetarium

The Food and Drug Administration (FDA) has posted a variance application from Ingram Planetarium. The application is available for review on Regulations.gov, with the author listed as CDRH.

FDA Acknowledgment Letter to Axion Laser

The Food and Drug Administration (FDA) has issued an acknowledgment letter from its Division of Management and Budget (DMB) to Axion Laser. This notice confirms receipt of a submission, though no specific details about the submission's content or purpose are provided in the available information.

DePaul University Variance Application

The FDA has posted a variance application submitted by DePaul University's Idea Realization Laboratory. The document is available for review on the Regs.gov platform. No specific compliance actions or deadlines are indicated for other entities.

FDA Variance Approval Letter to Dapper Rave, LLC

The Food and Drug Administration (FDA) has issued a variance approval letter to Dapper Rave, LLC, through its Center for Devices and Radiological Health (CDRH). This document signifies an approval for a specific variance requested by the company.

FDA Variance Approval Letter

The Food and Drug Administration (FDA) has issued a variance approval letter to Laina Callow. The letter, originating from the Center for Devices and Radiological Health (CDRH), indicates a specific approval related to a medical device or process. A redacted version is available for public review.

FDA Variance Amendment from DePaul University Idea Realization Laboratory

The Food and Drug Administration (FDA) has posted a variance amendment submitted by DePaul University's Idea Realization Laboratory. The document is available for review on the Regs.gov platform, with an associated attachment from the Center for Devices and Radiological Health (CDRH).

FDA Complaint Document Details

The Food and Drug Administration (FDA) has posted details regarding a complaint document, with the information made available on March 26, 2026. The document is related to the Center for Tobacco Products (CTP) and is available for download.

FDA Complaint Document - Closed for Comments

The Food and Drug Administration (FDA) has opened a public comment period for a new complaint document, identified by docket number FDA-2026-H-2944. The comment period is scheduled to close on March 26th.

FDA Completeness Assessment Correspondence

The Food and Drug Administration (FDA) has posted Completeness Assessment Correspondence related to drug applications. This notice indicates that documentation is available for review via the provided URL, though no specific documents are directly viewable or downloadable from the initial posting.

FDA Variance Approval Letter to DePaul University

The FDA's Center for Devices and Radiological Health (CDRH) has issued a variance approval letter to DePaul University's Idea Realization Laboratory. This document signifies approval for a specific variance related to medical device development or testing.

FDA Variance Application from Axion Laser

The Food and Drug Administration (FDA) has posted a variance application from Axion Laser. This document is available for review on the FDA's regulations.gov portal.

Meloxicam Pharmaceutical Composition and Application

The USPTO has published a patent application (US20260083748A1) for a pharmaceutical composition containing meloxicam, a composite solvent, and an acidic pH regulator. The assignee is Beijing Tide Pharmaceutical Co., Ltd. This application details a preparation method and its application, focusing on a formulation that avoids organic solvents for increased safety and reduced environmental impact.

Patent Application: T-cell receptors target mutant RAS for cancer treatment

The USPTO has published patent application US20260083847A1 concerning T-cell receptors and compositions for treating cancer associated with mutant RAS. The application details methods and compositions involving T-cell receptors that bind to specific mutant RAS peptide fragments in the context of specific HLA types.

Antimicrobial Compositions Patent Application

The USPTO has published a patent application (US20260083126A1) for antimicrobial compositions containing organosulfur compounds. The application, filed on September 8, 2023, describes compounds useful for treating microbial infections and for cleaning, disinfecting, or agricultural use.

Modified T-Cells for Bladder Cancer Treatment Application

The USPTO has published a patent application (US20260083849A1) detailing a method for treating bladder cancer using modified immunoresponsive cells. The application was filed on September 7, 2023, and is related to therapeutic applications in oncology.

CAR T-cell therapy combined with BTK inhibitors for cancer

The USPTO has published a new patent application (US20260083848A1) detailing a combination therapy for cancer treatment. The application describes the use of CAR T-cell therapy with BTK inhibitors for treating hematological malignancies. This represents a new disclosure in the field of cancer therapeutics.

Chemical Compound with Triazine Group and Production Method

The USPTO has published a patent application (US20260085087A1) for a chemical compound comprising a triazine group and its production method. The application relates to novel nucleotides and oligonucleotides with modified phosphate groups, potentially useful in diagnostics, gene therapy, and treating bacterial and viral diseases, including COVID-19.

USPTO Patent for Therapeutic Compounds Treating Cancer

The USPTO has published patent application US20260085059A1 for therapeutic compounds and methods of use in treating cancer. The patent was assigned to Servier Pharmaceuticals LLC and lists Samuel V. Agresta et al. as inventors. The application was filed on May 7, 2025.

Proteoglycan Mimetics for Wound Healing and Angiogenesis

The USPTO has published a new patent application, US20260083852A1, detailing proteoglycan mimetics for enhanced wound healing and angiogenesis. The application describes compounds designed to support tissue regeneration and promote vascular repair, potentially limiting systemic exposure to VEGF activity.

Patent for Radiation Dose Enhancement and Tumor Delineation

The USPTO has published a new patent application (US20260083850A1) for compounds, compositions, and methods related to radiation dose enhancement and tumor delineation. The application, assigned to the University of Connecticut, focuses on using barium nanoparticles for improved radiation therapy and tumor identification.

USPTO Patent Application: Polynucleotides Targeting NR4A3

The USPTO has published a patent application (US20260083846A1) filed by Lyell Immunopharma, Inc. The application describes polynucleotides designed to target the NR4A3 gene and their potential use in treating diseases, including cancer. The patent is scheduled to be published on March 26, 2026.

Cellicure, Inc. Patent Application for Engineered Immune Cells

The USPTO has published a patent application (US20260083845A1) filed by Cellicure, Inc. on September 22, 2023. The application details engineered immune cells, specifically chimeric antigen receptors (CARs) for enhanced killing activities, primarily targeting cancer treatment.

Immune Cells Target EpCAM for Tumor Treatment

The USPTO has published a patent application (US20260083843A1) from SUZHOU IMMUNOHEAD BIOTECHNOLOGY CO., LTD. The application details the use of immune cells that target EpCAM for the prevention or treatment of metastatic tumors expressing EpCAM.

Patent Application: Vaccine for Bordetella pertussis using antigen peptides

The USPTO has published a patent application (US20260083833A1) for a vaccine against Bordetella pertussis using antigen peptides. The application details a method for preventing infection by targeting specific peptides processed and presented by CD4+ T cells. This relates to ongoing research and development in vaccine technology.

Novel agent for Alzheimer's treatment using dynamin 1 peptide

The USPTO has published a new patent application (US20260083826A1) from the Okinawa Institute of Science and Technology School Corporation for a novel agent to treat Alzheimer's disease. The application describes a peptide corresponding to dynamin 1, potentially encapsulated in nanoparticles for improved brain delivery.

USPTO Patent Application for WNT-Related Cancer Vaccines

The USPTO has published a patent application (US20260083831A1) filed by Geneos Therapeutics, Inc. The application details compositions and methods for treating WNT-related cancers using nucleic acid sequences encoding tumor-specific antigens, potentially in combination with checkpoint inhibitors.

Patent Application for Biodegradable Particles Delivering Therapeutic Agents

The USPTO has published a new patent application (US20260083830A1) for biodegradable polymeric particles designed for the extended, controlled release of positively charged therapeutic agents at neutral pH. The application details microparticles and nanoparticles comprising an uncapped polymer matrix and a net positively charged therapeutic agent.

Patent Application for DNase Enzyme Therapy for Tumor Microenvironment Immunomodulation

The USPTO has published a patent application (US20260083827A1) filed by CLS THERAPEUTICS LIMITED for methods of immunomodulating the tumor microenvironment using DNase enzyme therapy. The application details methods involving the administration of DNase enzyme, alone or with other agents, to combat immunosuppressive tumor cell microenvironments.

Wound healing composition with amino acids and fish collagen

The USPTO has published a new patent application detailing a composition for promoting wound healing. The composition includes an amino acid mixture and fish collagen, with a method for its administration also described. This application was filed on September 20, 2024.

Ocular Insulin Delivery Enhanced by Prostaglandin Analogues Patent Application

The USPTO has published a patent application (US20260083822A1) for a novel ocular insulin delivery system. The invention utilizes prostaglandin analogues to enhance insulin permeability across ocular tissues, offering a non-invasive alternative to injections for therapeutic effects.

Patent Application: Autism Symptom Treatment via Neurotensin Receptor Activation

The USPTO has published a new patent application (US20260083820A1) from the New York Institute of Technology for methods and formulations to treat autism symptoms by activating neurotensin receptor 1 (NTSR1) without causing significant lethargy. The application was filed on October 3, 2025.

Cancer Treatment Using TTFields and Interferon Gamma Compositions

The USPTO has published a new patent application detailing compositions, systems, and methods for treating cancer using Tumor Treating Fields (TTFields) in combination with interferon gamma. The application, filed on September 18, 2025, outlines a method for reducing cancer cell viability and tumor volume.

Adjuvant Composition with STING Agonist and Aluminium Hydroxide

The USPTO has published a patent application by GlaxoSmithKline Biologicals SA for an adjuvant composition comprising a STING agonist and an aluminum-based adjuvant. The application details immunogenic compositions and their use in immunizing subjects.

Anti-tumor immune response enhancer patent application

The USPTO has published a new patent application, US20260085286A1, detailing an 'Anti-tumor immune response enhancer'. The application, filed by Kenichiro Hasumi, describes a composition comprising phospholipids to enhance anti-tumor activity and induce cytokine production.

Methods for Producing Retinal Pigment Epithelium Cells

The USPTO has published a new patent application detailing methods for producing retinal pigment epithelium (RPE) cells. The application describes specific culturing and replating techniques using laminin substrates to expand and mature RPE cells for potential therapeutic uses.

Stem cell-derived gastruloid model and construction method

The USPTO has published a patent application detailing a stem cell-derived gastruloid model and its construction method. This model simulates early embryonic development and can be used for drug screening and safety testing, particularly for early pregnancy applications.

Patent Application for On-Board Lysis Capsule in Fluidic Cartridge

The USPTO has published a patent application (US20260085275A1) for an on-board lysis capsule designed for fluidic cartridges. The capsule contains beads and magnetic elements for cell lysis and may include an internal control for assay validation. The application was filed by Gen-Probe Incorporated.

Patent Application: Culture Medium Production Using Microbial Co-Hydrolysis

The USPTO has published a patent application (US20260085281A1) detailing a method for producing culture medium through microbial co-hydrolysis of plant proteins. The application, filed on April 10, 2025, aims to improve soil and cultivation effects using waste seasoning.

Patent Application for Modified Microorganisms Consuming Xylose

The USPTO has published a patent application (US20260085280A1) for methods of modifying microorganisms to increase xylose consumption. The application, filed by MARA RENEWABLES CORPORATION, details processes for enhancing microbial growth on hemicellulosic carbohydrates.

Corynebacterium Mutant Strain for Enhanced L-Arginine or L-Citrulline Productivity

The USPTO has published a patent application by Daesang Corporation for a Corynebacterium mutant strain designed for enhanced L-arginine or L-citrulline productivity. The application details a method for producing these amino acids using the modified strain, which exhibits increased activity in the L-arginine biosynthesis pathway.

Genetically Modified Clostridium Acetobutylicum for Lignocellulosic Biomass

The USPTO has published a patent application (US20260085278A1) detailing genetically modified Clostridium acetobutylicum strains designed for efficient growth on lignocellulosic biomass. The application, filed by Institut National des Sciences Appliquees de Toulouse, describes overexpressing specific operons to enhance biomass conversion for producing bulk chemicals like ethanol and butanol.

Patent Application for Microorganism and Ergothioneine Production

The USPTO has published a patent application (US20260085277A1) from Kureha Corporation detailing a novel microorganism and a method for producing ergothioneine. The application includes specific microorganism accessions and CPC classifications related to biotechnology and chemical synthesis.

Patent Application for Mycelium Substrate Preparation

The USPTO has published a new patent application (US20260085276A1) detailing means and methods for preparing a mycelium-colonized substrate. The application, filed on September 25, 2023, describes a method involving incubating a substrate with synthetic granulometry regulators and a solid-state mycelium bioreactor.

Patent Application for Fermentation Process Standardization

The USPTO has published a patent application (US20260085274A1) from Precision Fermentation, Inc. The application details methods and systems for standardizing fermentation processes, including constructing baseline databases and initiating new process instances. This is a new patent application filing.

Electroporation Apparatus and Methods Patent Application

The USPTO has published a patent application (US20260085268A1) filed by MaxCyte, Inc. on September 6, 2023. The application describes an apparatus and methods for electroporation of cells, including safety features like an emergency stop button. This is a new patent application and does not impose new regulatory requirements.

USPTO patent application for bioprocess on cell cultures

The USPTO has published a patent application (US20260085266A1) detailing a method for performing a bioprocess on liquid immune or naive cell cultures. The application, filed on December 13, 2022, describes an integrated bioprocessing system with preconfigurable cartridges for cell therapy.

Chimeric Transposases and Fusion Proteins Patent Application

The USPTO has published a new patent application (US20260085332A1) detailing chimeric transposases and fusion proteins. The application, filed on October 3, 2025, by inventors Joseph S. Lucas, Blair B. Madison, and Olga Batalov, covers polynucleotides, vectors, and methods for modifying cells using these proteins.

Alpha-amylase variants and polynucleotides patent application

The USPTO has published a new patent application, US20260085261A1, from Novozymes A/S concerning alpha-amylase variants and related polynucleotides. The application details specific molecular constructs and their potential uses.

Breast Cancer Detection Kit, Device, and Method Patent Application

The USPTO has published a patent application (US20260085359A1) from TORAY INDUSTRIES, INC. for a breast cancer detection kit, device, and method. The application describes a kit or device comprising nucleic acids that specifically bind to a miRNA in a subject's sample, and a method for detecting breast cancer by measuring the miRNA in vitro.

Methods for rapid multiplex HLA genotyping and transcript quantitation

The USPTO has published a new patent application detailing methods for rapid multiplex HLA genotyping and transcript quantitation using nanopore technology. The application, assigned to The University of North Carolina at Chapel Hill, outlines techniques for determining HLA status and genotyping donor cells for transplantation.

Viral Protein Expression Patent Application

The USPTO has published a new patent application, US20260085328A1, filed on September 8, 2023. The application describes methods and systems for producing adeno-associated virus (AAV) particles using insect cells.

Patent Application: Disruption of GROOT Gene Function Increases Plant Biomass

The USPTO has published a patent application (US20260085325A1) from the Salk Institute for Biological Studies detailing methods to enhance plant biomass and seed size by reducing the expression of GROOT1, GROOT2, and GROOT3 genes. The application describes compositions and transformed plants generated using these methods.

Method for Detecting Polynucleotide Analyte Using CRISPR/Cas Effector

The USPTO has published a new patent application detailing a method for detecting polynucleotide analytes using CRISPR/Cas effector technology. The application, filed by inventors from USPTO, describes a method involving a cleaving agent with flap endonuclease activity and a type V CRISPR/Cas effector protein, specifically a Cast2 protein.

Patent Application for Pseudomonas Recombinant Protein Expression

The USPTO has published a new patent application, US20260085338A1, detailing a Pseudomonas sp. strain for recombinant protein expression. The application was filed on September 6, 2023, and relates to novel expression systems for biotechnological applications.

Patent Application for Plant Regulatory Elements and Uses

The USPTO has published a patent application (US20260085324A1) detailing novel synthetic small nuclear RNA (snRNA) promoters for CRISPR-mediated gene modifications in plants. The application, filed on October 3, 2025, includes methods and compositions for developing plants with modified genomes using these promoters.

Patent Application for Metabolism Disease Therapeutic Agents

The USPTO has published a new patent application (US20260085322A1) for therapeutic agents targeting metabolism-associated diseases, such as MAFLD. The application was filed on September 6, 2023, by inventors from the USPTO.

Method for Producing Oil Composition via Biomass Fermentation

The USPTO has published a patent application detailing a method for producing an oil composition through the fermentation of biomass using specific yeast strains. The application outlines a preparation stage, a fermentation stage with controlled temperature and pH, and an oil procurement stage involving mechanical cell lysis.

Engineered Ketoreductases for Chiral Alcohol Preparation

The USPTO has published a patent application (US20260085334A1) for engineered ketoreductase polypeptides developed by Enzymaster (Ningbo) Bio-Engineering Co., Ltd. The patent describes enzymes capable of preparing chiral alcohols with high catalytic activity, stereoselectivity, thermal stability, and solvent tolerance.

Patent Application: Iron Metabolism Targets for Obesity Treatment

The USPTO has published a new patent application (US20260085321A1) detailing methods for treating obesity by inhibiting specific iron metabolism genes. The application, filed on September 24, 2025, by inventor Richard Possemato, proposes inducing weight loss through increased lipid catabolism.

GalNAc Monomer for Liver-Targeted Nucleic Acid Drug Delivery

The USPTO has published a patent application detailing a GalNAc monomer for liver-targeted delivery of small nucleic acid drugs. The application, filed by inventors Zeao Huang et al., describes a compound that enhances drug efficacy through efficient liver targeting.

US Patent Application for PDCD1 Knockout RNA Molecule

The USPTO has published a new patent application (US20260085331A1) for an RNA molecule designed for biallelic knockout of PDCD1. The application, filed on September 18, 2023, details compositions comprising RNA molecules with specific guide sequences and their methods of use.

Patent Application for Propagator Cells and Phage Propagation Methods

The USPTO has published a new patent application (US20260085296A1) detailing propagator cells and methods for propagating phage, particularly for delivering CRISPR-Cas components via probiotic organisms. The application was filed on December 4, 2025.

Method for Trans-Differentiating Non-Neuronal Cells into Neurons

The USPTO has published a patent application (US20260085284A1) from SHANGHAI GENEMAGIC BIOSCIENCES CO., LTD. for a method of trans-differentiating non-neuronal cells into neurons using specific regulators. The application was filed on August 30, 2023.

Patent Application: Compositions for Treating CHD2 Haploinsufficiency

The USPTO has published a patent application (US20260085319A1) for compositions and methods to treat CHD2 haploinsufficiency. The application details a method of increasing Chromodomain Helicase DNA Binding Protein 2 (CHD2) in neuronal cells using a nucleic acid agent.

Methods for Generating cDNA Library from RNA

The USPTO has published a patent application (US20260085308A1) detailing methods for the fast and efficient generation of cDNA libraries from RNA. The application, filed on September 11, 2023, by inventors Keith Brown, Steven Head, and Phillip Ordoukhanian, describes a method adaptable for automation.

Genome-wide insulator screening system disclosed

The USPTO has published a patent application detailing a genome-wide insulator screening system. The system, comprising specific MAI-seq vectors, is designed for high-sensitivity screening of genomic insulators and is applicable to any species.

Patent Application for Nucleic Acid Library Preparation

The USPTO has published a new patent application, US20260085306A1, detailing ligation-free methods for preparing nucleic acid libraries for high-throughput sequencing. The application was filed on January 16, 2024, and published on March 26, 2026.

Methods for adding polymers to ribonucleic acids

The USPTO has published a patent application detailing methods for adding polymers of non-canonical nucleotides to the 3' end of ribonucleic acids (RNA). The application, filed by inventors from institutions including the University of California, describes techniques that may be used for RNA analysis and identification. This publication represents a new patent application and does not impose immediate regulatory obligations.

Novel cell wall hydrolases target Cutibacterium acnes conditions

The USPTO has published a patent application (US20260085303A1) detailing novel cell wall hydrolases designed to target Cutibacterium acnes. The application describes compositions and uses for treating conditions associated with this bacterium.

Patent Application: Plant Pest Control using Cas12a2 Protein

The USPTO has published a patent application (US20260085302A1) from Confluence Genetics, LLC, detailing methods and compositions for controlling plant pests using Cas12a2 protein and guide polynucleotides. The application describes targeting specific DNA or RNA sequences within plant pests for elimination.

Method to enhance CAR-T cell efficacy using NOS inhibitor

The USPTO has published a patent application (US20260083844A1) detailing a method to enhance CAR-T cell efficacy by downregulating nitric oxide synthase (NOS). This application describes a potential therapeutic approach for treating B cell malignancies that are resistant to current CAR-T cell treatments.

Patent Application: Genome Modification Compositions and Methods

The USPTO has published a new patent application (US20260085301A1) from Confluence Genetics, LLC, detailing compositions and methods for targeting and eliminating cells with pre-determined DNA sequences using Cas12a2 protein. The application was filed on September 19, 2025.

Patent Application for Engineered Pyrococcus Enzymes

The USPTO has published patent application US20260085299A1 for engineered Pyrococcus enzymes designed for improved nucleotide analogue incorporation in DNA sequencing. The application was filed on May 27, 2025.

Method for Efficient Biosynthesis of Rebaudioside M2 Using Glycosyltransferase

The USPTO has published a patent application detailing a method for the efficient biosynthesis of rebaudioside M2 using glycosyltransferase. The assignee, GUILIN LAYN NATURAL INGREDIENTS CORP., claims this method provides an environmentally friendly way to produce rebaudioside M2 with no by-products, potentially reducing production costs.

Bacterial Superoxide Dismutases Patent Application

The USPTO has published a patent application (US20260085297A1) filed by Novozymes A/S for bacterial superoxide dismutases. The application, filed on August 29, 2025, describes polypeptides useful in animal feed additives for improving growth, performance, and health.

Patent Application for AAV Purification Using Anion Exchange Chromatography

The USPTO has published a patent application (US20260085295A1) detailing methods for purifying adeno-associated viruses (AAV) using anion exchange chromatography. The application, filed on September 23, 2025, by inventors Garima Thakur, Sheldon Robert Mink, and Andrew David Tustian, focuses on enhancing purification efficiency and concentration.

Process for Producing Purified Rhabdovirus from Cell Culture

The USPTO has published a patent application detailing a process for producing a purified rhabdovirus from cell culture, specifically oncolytic rhabdoviruses like vesicular stomatitis virus. The application, filed on August 21, 2025, outlines methods for both upstream and downstream processing.

USPTO Patent Application for Body Fluid Sample Transport Solution

The USPTO has published a new patent application (US20260085293A1) detailing a solution and method for transporting or storing body fluid samples. The application, filed on March 27, 2024, by inventors Mitsumi NISHI, Noriko MIYAUCHI, and Rieko SHIMAMURA, describes a solution containing specific active ingredients for sample preservation.

Minimal Essential Media for Human Induced Pluripotent Stem Cells

The USPTO has published a patent application (US20260085292A1) detailing minimal essential media for culturing human induced pluripotent stem cells (iPSCs). The application was filed on September 11, 2023, by inventor Paul Wesley Burridge.

Patent Application: Diabetes Prevention/Treatment by Myeloid Suppressor Cell Activity

The USPTO has published a new patent application (US20260085291A1) from CREATIVE MEDICAL TECHNOLOGIES, INC. The application details methods and compositions for preventing or treating Type 1 diabetes by augmenting myeloid suppressor cell activity, potentially involving conditioned immune cells or exogenous suppressor cells.

Patent Application for Feeder Cells and Cell Sheet Production

The USPTO has published a new patent application (US20260085290A1) filed by DAI NIPPON PRINTING CO., LTD. The application details a method for producing feeder cells and cell sheets, derived from pluripotent stem cells, intended for maintaining or proliferating difficult-to-culture cells. This is a standard publication of a patent application.

Use of G007-LK for Osteogenic Differentiation and Bone Regeneration

The USPTO has published patent application US20260085289A1, detailing the use of a compound known as G007-LK. The application, filed by the Hospital of Stomatology, Guangzhou Medical University, describes G007-LK's potential to promote osteogenic differentiation of dental stem cells and aid in bone tissue regeneration.

CRISPR/Cas13a Kit for Rapid ALV-J Detection

The USPTO has published a patent application for a CRISPR/Cas13a kit designed for the rapid detection of avian leukosis virus subgroup J (ALV-J). This application details a method combining CRISPR/Cas13a with recombinase aided amplification for improved sensitivity and specificity in detecting ALV-J.

Patent Application: Conditioned Media, Cultured Cells Production

The USPTO has published a new patent application, US20260083818A1, detailing a system and method for the production, formulation, and use of conditioned media and cultured cells. The application was filed on May 7, 2025, and describes techniques for culturing various cell types, including animal and plant cells, together.

mRNA Vaccine and Immune Modulator Combination Patent Application

The USPTO has published a patent application (US20260083837A1) for a combination comprising mRNA molecules for vaccines or therapeutic proteins, along with immune-modulating mRNA. The application details combinations for improved or reduced immunogenicity to increase efficacy, and relates to host cells, pharmaceutical compositions, vaccines, and kits for medical use.

Patent Application: Alpha-Glucosidase Compositions for Pompe Disease Treatment

The USPTO has published a new patent application (US20260083829A1) from Amicus Therapeutics, Inc. The application details compositions comprising high concentrations of acid alpha-glucosidase and active site-specific chaperones for treating Pompe disease. It also covers methods for increasing enzyme stability.

Patent Application for Treating DNAse1 Deficiency Diseases

The USPTO has published a new patent application (US20260083828A1) detailing compositions and methods for treating diseases associated with DNAse1 and/or DNAse1L3 deficiency. The application was filed on September 11, 2025, by inventors Demetrios Braddock, Paul Stabach, and Ethan Lester.

Patent Application for Engineered Bacteriophage Transducing Particles Production

The USPTO has published a new patent application (US20260083787A1) from TROBIX BIO LTD. for systems and methods for producing engineered bacteriophage transducing particles. The application details novel approaches for manipulating bacterial populations using these particles and associated regulatory elements.

Antimicrobial use of Micrococcus porci against Staphylococcus species

The USPTO has published a patent application detailing the selective antimicrobial use of Micrococcus porci against harmful Staphylococcus species. The application describes compositions comprising Micrococcus porci for use in cosmetics, quasi-drugs, external skin preparations, or medicines.

Patent Application: Complex for Cartilage Differentiation

The USPTO has published a new patent application (US20260083780A1) detailing a complex for promoting cartilage differentiation. The application describes a method for fabricating cartilage and a pharmaceutical composition for treating arthropathy, filed on June 2, 2025.

Edible Aerial Mycelium Patent Application

The USPTO has published a patent application (US20260083160A1) filed on November 5, 2023, for edible aerial mycelium, methods of preparation, and food products containing them. The application includes hybrid food products with aerial mycelium and meat.

Coffee Fermentation Using Pichia Kluyveri and Lactiplantibacillus Plantarum

The USPTO has published a patent application (US20260083149A1) from CHR. HANSEN A/S detailing a method for coffee fermentation using specific yeast and bacteria strains. The application focuses on improving coffee bean and beverage production through controlled fermentation processes.

Delayed Harvest Methods for Short Stature Corn Plants

The USPTO has published a patent application (US20260083046A1) detailing methods for delayed harvesting of short stature corn plants. The application, filed on October 23, 2025, aims to provide growers with a flexible harvesting window to optimize drying or seed access without increasing yield loss risk.

Method Predicts Prime Editing Efficiency in Different Cell Types

The USPTO has published a patent application (US20260088126A1) detailing a method and device for predicting prime editing efficiency in various cell types and prime editor types. The application, filed by Yonsei University, focuses on training predictive models for both on-target and off-target prime editing efficiency.

Patent Application for mRNA Design

The USPTO has published patent application US20260088125A1 concerning methods for designing synthetic RNA molecules, specifically for mRNA design. The application details a process for obtaining coding sequences and selecting regions for synthetic RNA molecule production.

Patent Application for Cell Manipulation Device and Method

The USPTO has published a new patent application (US20260086001A1) for a cell manipulation device and method. The application, filed on December 1, 2025, describes a technique for culturing cells by attaching them to an air bubble formed in a liquid flow path. This is a routine publication of a patent application.

Cardio-Tox TEEM Model for Cardiotoxicity and Arrhythmia Risk Assessment

The USPTO has published a patent application detailing the Cardio-Tox Tissue Engineered Model (TEEM). This in vitro model uses 3D human heart microtissues to assess cardiotoxicity and arrhythmia risk from test compounds, aiming to establish safe human exposure levels for environmental and pharmaceutical substances.

Viscoelastic Hydrogel Regulates Organoid Patterning and Vascularization

The USPTO has published a new patent application, US20260086082A1, detailing a viscoelastic hydrogel for regulating organoid patterning and vascularization. The application, filed by inventors Changchun Zeng, Yan Li, and Xingchi Chen, focuses on a spinal cord model.

Viscoelastic Hydrogel Regulates Organoid Patterning and Vascularization

The USPTO has published a new patent application, US20260086081A1, detailing a viscoelastic hydrogel for regulating organoid patterning and vascularization. The application, filed on April 10, 2025, describes spinal cord models using methacrylated hyaluronic acid and dopamine-modified hyaluronic acid.

Ovarian and Uterine Organoid Production and Pharmaceutical Screening

The USPTO has published a patent application detailing methods for producing ovarian and uterine organoids from stem cells. These organoids are intended for use in screening pharmaceutical interventions for diseases and for applications in hormone replacement therapy and assisted reproduction technologies.

Enzyme-containing article with water barrier properties

The USPTO has published a new patent application, US20260085163A1, detailing an enzyme-containing biodegradable single-layer article with water barrier properties. The application was filed by Vincent Legrand and includes various CPC classifications related to polymers and enzymes.

Patent Application: Method of Differentiating Pluripotent Stem Cells to Hematopoietic Cells

The USPTO has published a patent application (US20260085288A1) detailing a method for differentiating pluripotent stem cells into hematopoietic precursor and stem cells. The application, filed by Boris Greber and Daniel Terheyden-Keighley, outlines a process using specific induction cocktails for generating immune cells like NK cells.

Therapeutic Macrophages Patent Application

The USPTO has published a patent application (US20260085287A1) filed by Resolution Therapeutics Limited for therapeutic macrophages genetically engineered to overexpress Interleukin-10 (IL-10) or IL-10 in combination with Matrix Metallopeptidase 9 (MMP9). This application relates to potential treatments for inflammatory conditions.

HANPO PATCH Trademark Application - Herbal Mud Packs

The USPTO has received an intent-to-use trademark application for 'HANPO PATCH' for goods including herbal mud packs, medicinal herbs, and dressings. The application was filed on March 25, 2026, with an intended use date of March 26, 2026.

VERO Intent to Use Trademark Application Filed

The USPTO has received an intent-to-use trademark application for the mark 'VERO'. The application, filed on March 25, 2026, covers dietary and nutritional supplements, including satiety beverages and powdered drink mixes.

SMILE+ DAILY ORAL DEFENSE Trademark Application

The USPTO has received an intent-to-use trademark application for 'SMILE+ DAILY ORAL DEFENSE' filed on March 25, 2026. The application covers dietary and nutritional supplements. This filing indicates a future intention to use the mark in commerce.

CMS Seeks Public Comment on Information Collection Activities

The Centers for Medicare & Medicaid Services (CMS) is seeking public comment on its intention to collect information, specifically regarding the State-based Exchange Annual Reporting Tool (SMART). This notice provides an opportunity for comment on the necessity, utility, and burden of the proposed information collection.

CMS Seeks Public Comment on Information Collection Activities

The Centers for Medicare & Medicaid Services (CMS) is seeking public comment on its intention to collect information from the public, as required by the Paperwork Reduction Act. This notice provides an opportunity for comment on the necessity, utility, and burden of proposed information collections, including those related to Qualified Health Plan (QHP) certification.

FDA Approves Kresladi, First Gene Therapy for Severe LAD-I

The FDA has approved Kresladi (marnetegragene autotemcel), the first gene therapy for severe Leukocyte Adhesion Deficiency Type I (LAD-I) in pediatric patients. This accelerated approval offers a new treatment option for a rare inherited immune deficiency, targeting the underlying genetic cause of the disease.

Patent Application: Acetic Acid and Hypochlorous Acid Compositions for Skin Trauma Treatment

The USPTO has published a new patent application (US20260083774A1) detailing compositions containing hypochlorous acid and acetic acid for treating skin trauma and biofilms. The application was filed on September 22, 2025, and published on March 26, 2026.

Metal nanoparticle agglomerates for infection control and water purification

The USPTO has published a patent application detailing the use of metal nanoparticle agglomerates for infection control and water purification. The application describes antiseptic substrates and fluid formulations incorporating these agglomerates for topical or oral use, aiming to provide infection control against infective agents.

Patent Application: Cytotoxic Lymphocyte Activation and Expansion

The USPTO has published patent application US20260083776A1 concerning methods for activating and expanding cytotoxic lymphocytes with decreased exhaustion potential. The application details micropatterned surfaces and biofunctionalization techniques for cell expansion, potentially impacting future therapeutic development in oncology.

Patent Application: Sigmari Ligand for Pancreatic Cancer Treatment

The USPTO has published a patent application (US20260083725A1) for a Sigmari Ligand for the treatment of pancreatic cancer. The application details a method involving a Sig-1R ligand to inhibit tumor growth and metastasis, filed on August 9, 2023.

USPTO Patent Application for Compounds Targeting Pax3/Foxo1 Fusion Protein

The USPTO has published patent application US20260083724A1, filed by Georgetown University, for novel compounds designed to target the PAX3::FOXO1 fusion protein. These compounds aim to reduce protein levels and treat fusion-positive rhabdomyosarcoma.

Pegylated Menaquinol Compositions and Treatment Methods Patent Application

The USPTO has published a patent application (US20260083773A1) for pegylated menaquinol compositions and methods of treatment. The application, filed on December 5, 2025, discloses isolated, stable, and biologically active pegylated menaquinol derivatives for treating various diseases.

Patent Application for Fiber-Based Prebiotic Dietary Supplements

The USPTO has published a patent application (US20260083772A1) for powder compositions comprising fiber intended for use as a prebiotic dietary supplement. The application details therapeutic ingredients and manufacturing processes aimed at improving gut microbiome and overall gut health.

Biopolymers for Ophthalmic Use Patent Application

The USPTO has published a patent application (US20260083771A1) for biopolymers intended for ophthalmic use, filed by ExoPolymer, Inc. The application details biopolymers comprising repeating polysaccharide units, their preparations, ophthalmic compositions, and methods of use.

Cancer Treatment Methods Using Tumor Treating Fields, Chemotherapy, and Anti-Fibrotic Agents

The USPTO has published a patent application detailing methods for treating cancer. The application describes compositions and systems involving the concurrent application of tumor treating fields, chemotherapeutic agents, and anti-fibrotic agents to reduce cancer cell viability and tumor growth.

Deuterated Domperidone Formulations for Gastroparesis and Nausea

The USPTO has published a patent application (US20260083717A1) for deuterated domperidone formulations. These formulations are intended for treating gastroparesis, nausea, vomiting, and other related conditions. The application details specific excipient combinations for these pharmaceutical compositions.

Therapeutic Agent for ALS Inhibits Ferroptosis Using Tetrahydroquinoline Derivative

The USPTO has published a patent application (US20260083723A1) from Toray Industries, Inc. The application describes a therapeutic or preventive agent for amyotrophic lateral sclerosis (ALS) that inhibits ferroptosis, utilizing a tetrahydroquinoline derivative as the active ingredient. This filing details compositions and methods for treating ALS and inhibiting ferroptosis.

Patent Application: Childhood Atropine Formulation for Myopia Progression

The USPTO has published a patent application (US20260083720A1) filed by Vyluma Inc. for a storage-stable, low-dose atropine formulation (0.01%) intended to reduce myopia progression in children. The application details the formulation's unexpected effectiveness compared to a higher concentration.

Piperidine Urea Derivatives for Obesity Therapy Patent Application

The USPTO has published a patent application (US20260083718A1) filed by Astrizi Bio, Inc. The application describes piperidine urea derivatives for preventing, suppressing, or treating obesity, potentially in combination with GLP-1 receptor agonists.

USPTO Patent Application for Improving Sperm Quality

The USPTO has published a patent application (US20260083719A1) filed by The University of Adelaide for methods and products aimed at improving sperm quality. The application details the use of specific compounds, such as BGP-15, in assisted reproductive technologies.

Dosing regimen for treating PKU with piperidine inhibitor

The USPTO has published a new patent application (US20260083714A1) detailing a dosing regimen for treating phenylketonuria (PKU) using a piperidine inhibitor of SLC6A19 function. The application was filed on August 25, 2023, by inventors John Peter Throup and Heather Smith Blanchette.

Immunity Enhancing Composition with Amide Compound

The USPTO has published a patent application (US20260083715A1) for a composition containing a novel amide-based compound derived from amino acids. The composition is designed to enhance immunity by activating macrophage phagocytosis, aiding in the removal of pathogenic bacteria.

R-Trihexyphenidyl Patent for Movement Disorder Treatment

The USPTO has published a new patent application, US20260083716A1, filed by The Children's Mercy Hospital. The patent covers compositions and methods for treating movement disorders, such as dystonia, using high chiral purity R-trihexyphenidyl.

HIZENTRA solution recalled due to appearance out of specification

Health Canada has issued a recall for the HIZENTRA solution due to an appearance out of specification in lot P100834477. The recall is classified as Type II, indicating a low risk to health. End users are advised to consult healthcare providers before discontinuing use.

Novel LXR Modulators with Bicyclic Core for Treating Dyslipidemias

The USPTO has published a new patent application, US20260083704A1, detailing novel LXR modulators with a bicyclic core for treating dyslipidemias and related metabolic disorders. The application was filed on May 1, 2025, and published on March 26, 2026.

USPTO Patent Application for Transdermal Dexmedetomidine

The USPTO has published patent application US20260083705A1 for methods of using transdermal delivery patches containing dexmedetomidine to treat agitation. The application was filed on September 24, 2025, by inventors Wan-Ning Song and Gary G. Kay.

Patent Application: Combination Pharmacological Interventions for Sleep Apnea

The USPTO has published patent application US20260083709A1, detailing a novel pharmacological intervention for treating obstructive sleep apnea. The application, filed on December 3, 2025, describes pharmaceutical compositions involving a combination of a norepinephrine reuptake inhibitor, muscarinic receptor antagonist, and carbonic anhydrase inhibitor.

USPTO Patent Application for Acute Migraine Treatment with Ubrogepant

The USPTO has published a new patent application (US20260083710A1) detailing methods for the acute treatment of migraine using the drug ubrogepant. The application includes specific claims related to treatment in patients with hepatic or renal impairment and those concurrently taking certain CYP3A4 modulators or BCRP/P-gp inhibitors.

Patent Application: Compounds for Inhibiting IL-17

The USPTO has published a patent application (US20260083708A1) detailing compounds for inhibiting IL-17 activity. The application, filed on December 1, 2025, describes compounds and methods for treating inflammatory and autoimmune disorders.

Patent for treating ocular autoimmune disorder comorbidities with roflumilast

The USPTO has published a new patent application (US20260083712A1) assigned to Iolyx Therapeutics, Inc. The patent describes methods for treating ocular comorbidities of autoimmune disorders, such as dry eye disease, using ophthalmic formulations of roflumilast. The application was filed on September 19, 2025.

Patent Application: Methods for treating epilepsy using 5HT receptor agonists

The USPTO has published a new patent application (US20260083706A1) detailing methods for treating epilepsy using 5HT receptor agonists. The application was filed on May 29, 2025, by inventor Scott C. Baraban.

Tinostamustine for T-cell prolymphocytic leukemia treatment patent

The USPTO has published a patent application (US20260083707A1) for Purdue Pharma L.P. detailing the use of tinostamustine for treating T-cell prolymphocytic leukemia. The application was filed on July 28, 2025.

Multilayered Microparticles for Controlled Release of Active Compounds

The USPTO has published a new patent application (US20260083713A1) detailing multilayered microparticles for controlled release of active compounds in liquid dosage forms. The application was filed on October 21, 2025, by inventors from Belgium.